title: Lack of Long-Term Neurologic Efficacy of Zileuton in Sjögren-Larsson's Syndrome.
authors.affiliation: CHU Clermont-Ferrand, Service de Pédiatrie, Hôpital Estaing, Clermont-Ferrand, France.|IGCNC, Université Clermont Auvergne, Clermont-Ferrand, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Sarret
authors.affiliation: APHP, Service de Neurologie Pédiatrique et Maladies Métaboliques, Hôpital Robert Debré, Paris, France.
authors.forename: Samia
authors.initials: S
authors.lastname: Pichard
authors.affiliation: APHP, Service de Neurologie Pédiatrique, Hôpital Armand Trousseau, Paris, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Afenjar
authors.affiliation: APHP, Service de Neurologie Pédiatrique et Maladies Métaboliques, Hôpital Robert Debré, Paris, France.|Inserm U1141, Université Paris Diderot Sorbonne-Paris Cité, DHU PROJECT, Hôpital Robert Debré, Paris, France.
authors.forename: Odile
authors.initials: O
authors.lastname: Boespflug-Tanguy
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D007223:Infant; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D017063:Outcome Assessment, Health Care; D016111:Sjogren-Larsson Syndrome / Q000188:drug therapy*
chemical_list: D016859:Lipoxygenase Inhibitors; C063449:zileuton; D006918:Hydroxyurea